Vaccine Composition Comprising An Immunoadjuvant Compound Consisting Of A Rho Gtpase Family Activator


This invention is based on the experimental finding that activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine. This invention concerns a vaccine composition including an immunoadjuvant compound, wherein the immunoadjuvant compound consists of a Rho GTPase activator.

Download PDF
Document Preview
Document History
  • Publication: Feb 2, 2010
  • Application: Feb 25, 2005
    US US 58950505 A
  • Priority: Feb 25, 2005
    EP EP 2005002105 W
  • Priority: Feb 26, 2004
    EP EP 04300100 A

Download Citation

Sign in to the Lens